Ann: Neuren Corporate Presentation, October 2019, page-7

Ok, so my numbers from the other day were out, in the USA, by about a third. Most of this releates to the fact that the company hasn't counted any of the population aged > 60. However, the company has now given us indicative numbers for the USA, Europe and Japan. Total is 119k. Multiply this by the $240k AUD potential revenue per person per annum, and we have an annual
market of $28.5 Billion.....Wow!
Also, buried on slide 19 is "Phase 1 trial in healthy volunteers planned in Australia". Again, wow! We may not be waiting until H2 2020 to get an indication as to how 2591 works in humans. I know if a family member of mine was suffering from either of these 3 cruel diseases, then I'd be contracting the company ASAP...
So, why this presentation...? Slide 28 shows the mix of retail vs Insto shareholders. It's out of whack, and I'm sure they would like more instos on the register. We also need funds to accelerate 2591 Phase 1 trials as referenced above. These funds could come from either milestone payments relating to the Acadia deal, partnering arrangements in Japan or Europe for Trofinide or a share placement to Instos. To be honest, if it was a placement, I wouldn't be at all concerned. In fact I feel we need some stronger holders to make sure we don't get sold for a song. They will put a line in the sand and say no a lot easier than us mum's and dad's.
So, well done Neuren, and let's go!!